Cullinan submits NDA for zipalertinib in first-line EGFR ex20ins NSCLC
Cullinan announced an NDA submission for zipalertinib in combination with chemotherapy under the FDA Real-Time Oncology Review program based on Phase 3 clinical data, with milestones potentially worth $100 million pending approval.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed